ArticleCancer cell2010
Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells.
Article in Cancer cell, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 127 citations in OpenAlex.
- Twist1 overexpression models an aggressive subtype of pancreatic ductal adenocarcinoma in vivo.Lab animal · 2026Article
- KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ductal epithelial MXD3 promotes disease progression in acute pancreatitis through Wnt/β-catenin-mediated inflammation and injury.Frontiers in physiology · 2026Article
- MultiplexedbioRxiv : the preprint server for biology · 2025Article
- Unraveling the Role of Ras Homolog Enriched in Brain (Rheb1 and Rheb2): Bridging Neuronal Dynamics and Cancer Pathogenesis through Mechanistic Target of Rapamycin Signaling.International journal of molecular sciences · 2024Review
- Development of a customizable mouse backbone spectral flow cytometry panel to delineate immune cell populations in normal and tumor tissues.Frontiers in immunology · 2024Article
- Iron overload induces cerebral endothelial senescence in aged mice and in primary culture in a sex-dependent manner.Aging cell · 2023Article
- Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer.Nature communications · 2023Article
- Senescence program and its reprogramming in pancreatic premalignancy.Cell death & disease · 2023Review
- Review
- MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis.Nature cancer · 2022Article
- Cancer-inducing niche: the force of chronic inflammation.British journal of cancer · 2022Review
- Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants.Nature biotechnology · 2022Article
- The landscape of human tissue and cell type specific expression and co-regulation of senescence genes.Molecular neurodegeneration · 2022Article
- Orchestration of mesenchymal plasticity and immune evasivenessFrontiers in oncology · 2022Review
- A pancreas tumor derived organoid study: from drug screen to precision medicine.Cancer cell international · 2021Review
- Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management.Trends in endocrinology and metabolism: TEM · 2021Review
- Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting.Frontiers in oncology · 2021Review
- Inactivation of the Euchromatic Histone-LysineFrontiers in cell and developmental biology · 2021Article
- Regulation and modulation of antitumor immunity in pancreatic cancer.Nature immunology · 2020Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Mutational activation of KRas is the first and most frequently detected genetic lesion in pancreatic ductal adenocarcinoma (PDAC). However, the precise role of oncogenic KRas in the pathogenesis of PDAC is not fully understood. Here, we report that the endogenous expression of oncogenic KRas suppresses premature senescence in primary pancreatic duct epithelial cells (PDEC). Oncogenic KRas-mediated senescence bypass is conferred by the upregulation of the basic helix-loop-helix transcription factor Twist that in turn abrogates p16(INK4A) induction. Moreover, the KRas-Twist-p16(INK4A) senescence bypass pathway is employed in vivo to prevent inflammation-associated senescence of pancreatic ductal epithelium. Our findings indicate that oncogenic KRas could contribute to PDAC initiation by protecting cells from entering a state of permanent growth arrest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.